Foghorn Therapeutics to Participate in the BMO Oncology Summit
01 Ottobre 2024 - 1:00PM
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage
biotechnology company pioneering a new class of medicines that
treat serious diseases by correcting abnormal gene expression,
today announced management's participation in investor meetings at
the BMO Oncology Summit being held Tuesday, October 8, 2024, in New
York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic
Control® platform and resulting broad pipeline have the potential
to transform the lives of people suffering from a wide spectrum of
diseases.
About Foghorn Therapeutics Foghorn®
Therapeutics is discovering and developing a novel class of
medicines targeting genetically determined dependencies within the
chromatin regulatory system. Through its proprietary scalable Gene
Traffic Control® platform, Foghorn is systematically studying,
identifying and validating potential drug targets within the
chromatin regulatory system. The Company is developing multiple
product candidates in oncology. Visit our website at
www.foghorntx.com for more information about the Company, and
follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors &
Media)khellsvik@foghorntx.com
Grafico Azioni Foghorn Therapeutics (NASDAQ:FHTX)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Foghorn Therapeutics (NASDAQ:FHTX)
Storico
Da Gen 2024 a Gen 2025
